Get a free copy of the research report on Moderna (MRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Based on data from, the stock currently has an average rating of “Hold” and an average price target of $179.13. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the stock. They issued a “neutral” rating for the company. Finally, Guggenheim started coverage on Moderna in a research note on Tuesday, April 25th. lifted their target price on Moderna from $127.00 to $145.00 and gave the company a “neutral” rating in a research note on Monday, April 10th. SVB Leerink downgraded Moderna from a “market perform” rating to an “underperform” rating and decreased their target price for the company from $111.00 to $93.00 in a research note on Friday, February 24th. Deutsche Bank Aktiengesellschaft lowered their price objective on Moderna from $225.00 to $200.00 and set a “buy” rating for the company in a report on Tuesday, February 28th. Morgan Stanley dropped their target price on Moderna from $185.00 to $153.00 in a research report on Friday, May 5th. Wall Street Analysts Forecast GrowthĪ number of brokerages have recently issued reports on MRNA. 63.11% of the stock is currently owned by institutional investors. Morgan Stanley now owns 4,187,353 shares of the company’s stock worth $752,133,000 after purchasing an additional 670,284 shares in the last quarter. Finally, Morgan Stanley raised its position in Moderna by 19.1% in the fourth quarter. Wellington Management Group LLP now owns 4,292,235 shares of the company’s stock valued at $659,201,000 after buying an additional 15,271 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Moderna by 0.4% during the first quarter. Geode Capital Management LLC now owns 6,244,957 shares of the company’s stock valued at $957,063,000 after buying an additional 77,265 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Moderna by 1.3% during the first quarter. MD now owns 6,443,409 shares of the company’s stock valued at $761,934,000 after buying an additional 3,051,035 shares during the last quarter. MD raised its position in shares of Moderna by 89.9% during the third quarter. now owns 46,466,171 shares of the company’s stock valued at $7,136,275,000 after acquiring an additional 1,679,425 shares during the period. boosted its holdings in Moderna by 3.7% during the first quarter. Institutional Investors Weigh In On ModernaĪ number of hedge funds have recently bought and sold shares of the company. will post -2.84 earnings per share for the current fiscal year. Equities analysts expect that Moderna, Inc. During the same period in the prior year, the business posted $8.58 earnings per share. Moderna’s revenue for the quarter was down 69.3% compared to the same quarter last year. Moderna had a net margin of 31.77% and a return on equity of 25.87%. The business had revenue of $1.86 billion for the quarter, compared to the consensus estimate of $1.17 billion. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.77) by $1.96. Moderna ( NASDAQ:MRNA – Get Rating) last posted its quarterly earnings results on Thursday, May 4th.
0 Comments
Leave a Reply. |